Source:http://linkedlifedata.com/resource/pubmed/id/14662882
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2003-12-9
|
| pubmed:abstractText |
E1-deleted adenoviral recombinants most commonly based on the human serotype 5 (AdHu5) have been shown thus far to induce unsurpassed transgene product-specific CD8(+) T cell responses. A large percentage of the adult human population carries neutralizing Abs due to natural exposures to AdHu5 virus. To circumvent reduction of the efficacy of adenovirus (Ad) vector-based vaccines by neutralizing Abs to the vaccine carrier, we developed E1-deleted adenoviral vaccine carriers based on simian serotypes. One of these carriers, termed AdC68, expressing a codon-optimized truncated form of gag of HIV-1 was shown previously to induce a potent transgene product-specific CD8(+) T cell response in mice. We constructed a second chimpanzee adenovirus vaccine vector, termed AdC6, also expressing the truncated gag of HIV-1. This vector, which belongs to a different serotype than the AdC68 virus, induces high frequencies of gag-specific CD8(+) T cells in mice including those pre-exposed to AdHu5 virus. Generation of an additional E1-deleted adenoviral vector of chimpanzee origin allows for sequential booster immunizations with heterologous vaccine carriers. In this study, we show that such heterologous prime boost regimens based on E1-deleted adenoviral vectors of different serotypes expressing the same transgene product are highly efficient in increasing the transgene product-specific CD8(+) T cell response. They are equivalent to sequential vaccinations with an E1-deleted Ad vector followed by booster immunization with a poxvirus vector and they surpass regimens based on DNA vaccine prime followed by a recombinant adenoviral vector boost.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/AIDS Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Adenovirus E1 Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes, T-Lymphocyte,
http://linkedlifedata.com/resource/pubmed/chemical/Gene Products, gag,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, DNA
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0022-1767
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
171
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
6774-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:14662882-AIDS Vaccines,
pubmed-meshheading:14662882-Adenovirus E1 Proteins,
pubmed-meshheading:14662882-Adenoviruses, Human,
pubmed-meshheading:14662882-Animals,
pubmed-meshheading:14662882-CD8-Positive T-Lymphocytes,
pubmed-meshheading:14662882-Cell Line,
pubmed-meshheading:14662882-Epitopes, T-Lymphocyte,
pubmed-meshheading:14662882-Female,
pubmed-meshheading:14662882-Gene Products, gag,
pubmed-meshheading:14662882-Genetic Vectors,
pubmed-meshheading:14662882-HIV Antigens,
pubmed-meshheading:14662882-HeLa Cells,
pubmed-meshheading:14662882-Humans,
pubmed-meshheading:14662882-Immunization, Secondary,
pubmed-meshheading:14662882-Immunization Schedule,
pubmed-meshheading:14662882-Injections, Intramuscular,
pubmed-meshheading:14662882-Lymphocyte Activation,
pubmed-meshheading:14662882-Mice,
pubmed-meshheading:14662882-Pan troglodytes,
pubmed-meshheading:14662882-Vaccines, DNA,
pubmed-meshheading:14662882-Vaccinia virus
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.
|
| pubmed:affiliation |
The Wistar Institute, University of Pennsylvania, Philadelphia, PA 19104, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|